CCL5 and neoplasm: Increasing evidence suggests that signaling from CCR5 and its ligand, C-C motif chemokine ligand 5 (CCL5), determines the immunosuppressive phenotypes of a huge proportion of immature myeloid cells, including MDSCs, at tumor-bearing sites [25].